Friday, December 7, 2012

Meda to buy OTC Insomnia product in the US

Medaa has agreed to acquire MidNite - an OTC insomnia product that holds dominant position in the OTC insomnia market. . Annualized revenues for MidNite are approximately 100 MSEK ($15 million).  After the MidNite acquisition, Meda’s OTC business in the US will have pro forma revenues of close to 400 MSEK.

MidNite's has four natural sleep ingredients include melatonin (1.5 mg. of European melatonin) and a proprietary blend of lavender, lemon balm and chamomile (22 mcg.). The blend has been developed to provide optimal sleep results.

Read more here: http://www.heraldonline.com/2012/12/07/4468062/meda-acquires-otc-product-in-the.html#storylink=cpy

Read more here: http://www.heraldonline.com/2012/12/07/4468062/meda-acquires-otc-product-in-the.html#storylink=cpy